Swedish Match logo
Consolidated Statement of Changes in Equity
Equity attributable to equity holders of the Parent
MSEK Note Share
capital		 Reserves Retained
earnings		 Total Minority
interest		 Total
equity
    19            
Equity at January 1, 2005   808 –96 3,867 4,579 481 5,060
Changed accounting principle, IAS 39     – 31 – 31 17 48
Translation differences for the year     – 707 – 707 34 741
Net change in fair value of available-for-sale                
financial instruments     – 9 – 9 – 9
Total income (expense) recognized directly in                
equity excluding transactions with equity owners     808  651  3,867  5,326  532  5,858
Net profit for the year     – – 1,769 1,769 9 1,777
Total recognized income and expense for the                
period excluding transactions with equity owners     808  651  5,636  7,095  541  7,635
Dividends     – – –612 –612 – –612
Acquisition of minority interest in General Cigar     – – – – –532 –532
Sale of shares in wimco     – – – – –6 –6
Cancellation of shares     –29 – 29 – – –
Reduction of par value     –389 – 389 – – –
Own shares acquired     – – –1,434 –1,434 – –1,434
Stock options exercised     – – 23 23 – 23
Share-based payments, IFRS 2     – – 8 8 – 8
Equity at December 31, 2005     390 651 4,039 5,079 3 5,083
Equity at January 1, 2006     390 651 4,039 5,079 3 5,083
Translation differences for the year     – –881 – –881 – –881
Sale of available-for-sale financial instruments     – –40 – –40 – – 40
Total income (expense) recognized directly in                
equity excluding transactions with equity owners     390 -270 4,039 4,158 3 4,162
Net profit for the year     – – 2,330 2,330 1 2,331
Total recognized income and expense for the                
period excluding transactions with equity owners     390 -270 6,369 6,489 4 6,493
Dividends     – – –627 –627 –1 –627
Cancellation of shares     –56 – 56 – – –
Bonus issue     56 – –56 – – –
Own shares acquired     – – –3,679 –3,679 – –3,679
Stock options exercised     – – 94 94 – 94
Share-based payments, IFRS 2     – – 10 10 – 10
Equity at December 31, 2006     390 –270 2,167 2,287 3 2,290
Consolidated Cash Flow Statement
MSEK   Note       2006 2005
    30          
Operating activities              
Profit before income tax           3,167 2,696
Adjustments for non-cash items and other           116 323
Income tax paid           –1,732 – 606
Cash flow from operating activities before changes in working capital           1,551 2,413
Cash flow from changes in working capital            
Increase (-)/Decrease (+) in inventories           – 97 51
Increase (-)/Decrease (+) in operating receivables           – 185 – 170
Increase (+)/Decrease (-) in operating liabilities           65 423
Net cash from operating activities           1,335 2,718
Investing activities            
Acquisition of property, plant and equipment*           – 304 – 328
Proceeds from sale of property, plant and equipment           100 628
Acquisition of intangible assets           – 270 –
Acquisition of minority shares in General Cigar           – –1,100
Acquisition of subsidiaries, net of cash acquired           – 29 –
Proceeds from sale of subsidiaries, net of cash disposed of           31 184
Investments in equity accounted investees             – 92
Change in non-current receivables           – 60 – 44
Change in other current investments           277 612
Net cash used in investing activities           – 255 – 140
Financing activities            
Repurchase of own shares           –3,674 –1,434
Sale of treasury shares           94 23
Proceeds from non-current borrowing           5,512 1,685
Repayment of borrowings           –2,383 – 942
Dividends paid to equity holders of the Parent           – 627 – 612
Other           –86 –162
Net cash used in financing activities           –1,164 –1,441
Net increase/decrease in cash and cash equivalents           –85 1,137
Cash and cash equivalents at the beginning of the year           3,325 2,058
Effect of exchange rate fluctuations on cash and cash equivalents           –198 130
Cash and cash equivalents at end of year           3,042 3,325
* Includes investments in assets held for sale and biological assets.